AASTROM BIOSCIENCES, INC.

Aastrom Biosciences Management Discusses Q1 2013 Results - Earnings Call Transcript

Aastrom reports Q1 EPS (15c), consensus (19c)

Aastrom Biosciences Reports First Quarter 2013 Financial Results

Aastrom to Host First Quarter 2013 Investor Call on May 8, 2013

Aastrom files to sell $25M in common stock

Bioniche Interprets Trade Volume, NVDQ Sizzles, OMER To Be Eyed, BTX Signs Deal

Aastrom announces first patients treated in ixCELL-DCM clinical study of ixmyelocel-T

Burrill & Co / Maxim Group to co-host a conference

Aastrom Biosciences to Present at Multiple Conferences in April

Aastrom begins patient enrollment in ixCELL-DCM trial